Immunovant (IMVT) Depreciation & Amortization (CF) (2019 - 2026)
Immunovant (IMVT) reported Depreciation & Amortization (CF) of $96000.0 for Q1 2026, down 11.93% on a YoY basis from $109000.0 in Q1 2025, and down 4.95% quarter-over-quarter from $101000.0 in Q4 2025.
Immunovant (IMVT) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Immunovant has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $96000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 11.93% year-over-year to $96000.0; the trailing twelve-month figure through Mar 2026 stood at $409000.0 (up 8.49% YoY), and the FY2026 full-year result was $409000.0, up 8.49% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $96000.0, down from $101000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $109000.0 in Q1 2025, with the low at $39000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $73470.6 across 5 years, with a median of $64000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 77.27% — and 2026, when it retreated 11.93%.
- Immunovant's Depreciation & Amortization (CF) stood at $49000.0 in 2022, then climbed by 18.37% to $58000.0 in 2023, then surged by 70.69% to $99000.0 in 2024, then climbed by 2.02% to $101000.0 in 2025, then slipped by 4.95% to $96000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $96000.0 (Q1 2026), $101000.0 (Q4 2025), and $105000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | 96,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96,000.00 |
| Mar 31, 2026 | 96,000.00 |
| Dec 31, 2025 | 101,000.00 |
| Dec 31, 2025 | 101,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Dec 31, 2023 | 58,000.00 |